0001415889-23-013899.txt : 20231003 0001415889-23-013899.hdr.sgml : 20231003 20231003170050 ACCESSION NUMBER: 0001415889-23-013899 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230929 FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ben Zvi Shmuel CENTRAL INDEX KEY: 0001935668 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 231305050 MAIL ADDRESS: STREET 1: 2 SNUNIT STREET STREET 2: SCIENCE PARK, #455 CITY: CARMIEL STATE: L3 ZIP: 2161401 FORMER NAME: FORMER CONFORMED NAME: Zvi Shmuel Ben DATE OF NAME CHANGE: 20220628 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 201-696-9345 MAIL ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 4 1 form4-10032023_051016.xml X0508 4 2023-09-29 0001006281 Protalix BioTherapeutics, Inc. PLX 0001935668 Ben Zvi Shmuel C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET SCIENCE PARK, POB 455 CARMIEL L3 2161401 ISRAEL true false false false 0 Stock Option (Right to Buy) 1.66 2023-09-29 4 A 0 61676 0 A 2033-09-29 Common Stock 61676 61676 D The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032 and (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032. /s/ Eyal Rubin, Attorney-in-Fact 2023-10-03